• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MSB
Click for more information
2.64% $2.72

MESOBLAST LIMITED - Charts / Financials

Market Cap $3.130B  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

refresh Created with Sketch. REFRESH
Last update - 15.30pm 16/01/2025 (20 minute delay) ?
Day
Open $2.73   Day High $2.73   Day Low $2.68
Daily Volume 3100859
Bids   Sellers
Number Price Volume   Number Price Volume
26 $2.72 59205   68 $2.73 107273

Directors & Senior Management

Dr. Silviu Itescu Chief Executive Officer, Executive Director
Mr. William M. Burns Non-Executive Independent Vice Chairman of the Board
Mr. Andrew Chaponnel Interim Chief Financial Officer
Dr. Fiona See Senior Vice President, Head - Translational Research
Mr. Peter Howard General Counsel, Corporate Executive
Dr. Eric A. Rose Executive Director, Chief Medical Officer
Mr. Justin Horst Head - Manufacturing
Mr. Michael Schuster Pharma Partnering
Ms. Geraldine Storton Head - Regulatory Affairs and Quality Management
Mr. Paul Hughes Joint Company Secretary
Mrs. Jane Bell Non-Executive Independent Chairman of the Board
Mr. Philip J. Facchina Non-Executive Independent Director
Mr. Philip R. Krause Non-Executive Independent Director

Data source: Refinitiv

(20min delay)
Last
$2.72 		Change
0.070(2.64%) 		Mkt cap ! $3.130B
Open High Low Value Volume
$2.73 $2.73 $2.68 $8.398M 3.100M

Buyers (Bids)

No. Vol. Price($)
26 59205 $2.72
 

Sellers (Offers)

Price($) Vol. No.
$2.73 107273 68
View Market Depth
Last trade - 15.12pm 16/01/2025 (20 minute delay) ?
Last
$2.72 		  Change
0.070 ( 2.75 %)
Open High Low Volume
$2.72 $2.73 $2.68 821054
Last updated 15.30pm 16/01/2025 ?

Top Stories

Southern Cross Gold Consolidated's January 'IPO' is all a bit confusing. Here's what happened

Southern Cross Gold Consolidated will be ringing the bell on the ASX today at 3PM in Sydney, and while it is listed as a float, it’s a little more complicated than that @ today’s IPO is really arriving on a deferred settlement basis.In the simplest sense, this is a...
Tabcorp up more than 5% after appointing 'one of the world's most sought-after wagering executives' Tabcorp Holdings Ltd has seen its share price rise after announcing the appointment of top wagering executive Michael Fitzsimons
HotCopper Highlights: Your most watched stocks for Week 2, 2025 Welcome back! It's 2025, and traders are looking for stockpicking opportunities. Here's what HotCopper users are watching.
Dimerix signs up first patient for 'highly significant' paediatric clinical trial Dimerix Limited (ASX:DXB), a Melbourne-based biopharmaceutical company, has started recruitment for its first paediatric patient for the Phase 3 ACTION3 clinical trial in a major next step for the research.The trial will investigate the efficacy of DMX-200 in children aged 12 to 17 with focal seg...
Week 2 Wrap: Insignia denies Brookfield bid; Star teetering; 1.5C breached & Samsung’s AI TVs It's been a strange week, and it's the first of the year (sort of.) Exxon's suing Twiggy; Samsung's got AI TVs. Then there's climate change.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.